Reported Saturday, Cytokinetics Shares Additional GALACTIC-HF Insights At AHA 2024
Reported Saturday, Cytokinetics Shares Additional GALACTIC-HF Insights At AHA 2024
Cytokinetics, Incorporated (NASDAQ:CYTK) today announced new data from post-hoc analyses of GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), the Phase 3 cardiovascular outcomes clinical trial of omecamtiv mecarbil were presented at the American Heart Association Scientific Sessions 2024 in Chicago, IL.
Cytokinetics, Incorporated（納斯達克股票代碼：CYTK）今天公佈了對GALACTIC-HF（通過改善心力衰竭收縮力降低心臟不良預後的全球方法）事後分析的新數據，omecamtiv mecarbil的3期心血管療效臨床試驗已在伊利諾伊州芝加哥舉行的2024年美國心臟協會科學會議上公佈。
"These analyses reinforce the potential treatment benefit of omecamtiv mecarbil in patients from GALACTIC-HF who are at higher risk, such as older patients or those with a recent ventricular arrhythmia," said Stuart Kupfer, M.D., Senior Vice President, Chief Medical Officer. "As we prepare for the start of COMET-HF, the confirmatory Phase 3 clinical trial of omecamtiv mecarbil, we look forward to evaluating its potential to reduce the risk of adverse heart failure outcomes across the spectrum of these very high-risk patients failing guideline-directed medical therapy."
高級副總裁兼首席醫學官斯圖爾特·庫普弗萬博士說：「這些分析強化了omecamtiv mecarbil對GALACTIC-HF患者的潛在治療益處，例如老年患者或近期出現心室心律失常的患者。」「在我們爲Comet-HF（Omecamtiv mecarbil的3期確認性臨床試驗）的啓動做準備時，我們期待評估其在降低這些高危患者中因指南爲導向的藥物治療失敗而出現不良心力衰竭結果的風險的可能性。」
